Bronchoscopy — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Bronchoscopy is a minimally invasive endoscopic procedure in which a thin flexible or rigid tubular instrument (bronchoscope) equipped with a camera and light source is passed through the nose or mouth, through the vocal cords, and into the trachea and bronchial tree to directly visualise the airways. Flexible fibreoptic bronchoscopy is the standard technique performed under conscious sedation in an outpatient setting; it allows access to lobar, segmental, and subsegmental bronchi. Rigid bronchoscopy uses a metal tube passed under general anaesthesia and is reserved for therapeutic interventions requiring a large working channel — foreign body retrieval, massive haemorrhage, or airway stenting. Modern advanced bronchoscopic techniques include endobronchial ultrasound (EBUS), which uses an ultrasound transducer on the bronchoscope tip to guide real-time transbronchial needle aspiration (TBNA) of mediastinal and hilar lymph nodes — a critical tool for lung cancer staging. Navigational bronchoscopy (electromagnetic or robotic-assisted) extends access to peripheral lung lesions not reachable by conventional bronchoscopy. Bronchoscopy serves both diagnostic and therapeutic purposes across a wide spectrum of pulmonary and airway diseases. Bronchoscopy is a minimally invasive endoscopic procedure in which a thin flexible or rigid tubular instrument (bronchoscope) equipped with a camera and light source is passed through the nose or mouth, through the larynx and vocal cords, and into the trachea and bronchial tree to visualise the airways, obtain tissue samples, and perform therapeutic interventions. Flexible bronchoscopy is performed under conscious sedation in an endoscopy suite; rigid bronchoscopy requires general anaesthesia in an operating theatre. Bronchoscopy was first performed in 1897 by Gustav Killian, who removed a pork bone from a patient's right main bronchus. Modern video bronchoscopy with high-definition imaging, endobronchial ultrasound (EBUS), and electromagnetic navigation systems have dramatically expanded both diagnostic and therapeutic capabilities. Bronchoscopy is performed by respiratory physicians, pulmonologists, and thoracic surgeons.

Bronchoscopy is indicated for a range of diagnostic and therapeutic indications. Diagnostic indications include unexplained haemoptysis (coughing blood) requiring airway inspection and biopsy, a lung mass or consolidation on CT scan requiring tissue diagnosis, persistent cough or atelectasis unexplained by other investigations, suspected endobronchial tumour, investigation of recurrent infections suggesting bronchiectasis or foreign body, and bronchoalveolar lavage (BAL) for diagnosis of interstitial lung disease, hypersensitivity pneumonitis, or immunosuppressed patients with pneumonia. Mediastinal lymphadenopathy requiring staging for lung cancer or sarcoidosis is the primary indication for EBUS-guided TBNA, which has replaced surgical mediastinoscopy in many centres. Therapeutic indications include foreign body removal (most common in children), management of central airway obstruction (stenting, tumour ablation by laser or cryotherapy), massive haemorrhage (balloon tamponade), difficult intubation assistance in ICU patients, and post-transplant airway anastomosis surveillance. Bronchoscopy is contraindicated with uncorrected severe hypoxaemia, uncorrected coagulopathy (INR >1.5 for biopsy procedures), or haemodynamic instability.

The patient fasts for 4–6 hours before the procedure. Topical anaesthetic (lidocaine) is administered to the nose, pharynx, and vocal cords via spray or nebulisation. Intravenous sedation — typically midazolam with or without fentanyl — is titrated to achieve conscious sedation; the patient remains rousable and protecting their airway. Supplemental oxygen is delivered by nasal cannula and oxygen saturation is monitored continuously throughout. The flexible bronchoscope (approximately 5–6 mm outer diameter) is advanced through a nostril or over the tongue into the hypopharynx, through the vocal cords (the patient is asked to breathe slowly), and into the trachea. The bronchoscopist systematically inspects the trachea, carina, both main bronchi, and all lobar and segmental bronchi. Biopsies are taken using cup forceps, bronchial brushings for cytology, and bronchoalveolar lavage for cell counts and microbiology. EBUS adds an ultrasound probe around the bronchoscope tip to visualise lymph nodes in real time; a 22-gauge needle is passed through the airway wall under ultrasound guidance to aspirate cellular material from mediastinal nodes. The procedure takes 20–45 minutes for diagnostic bronchoscopy and up to 90 minutes for EBUS staging. The patient fasts for 4–6 hours. Topical anaesthetic (lidocaine spray) is applied to the nose, pharynx, and vocal cords. Intravenous sedation (midazolam and fentanyl) is titrated to achieve comfortable cooperation. The bronchoscope is advanced through the nasal or oral route under direct vision. All visible bronchial segments are systematically examined to the level of the subsegmental bronchi. Bronchoalveolar lavage (BAL), transbronchial biopsy (TBB), endobronchial biopsy, or brushings are performed as indicated and sent for cytology, microbiology, and histology. EBUS combines the bronchoscope with a radial or linear ultrasound probe to visualise mediastinal lymph nodes and peripheral nodules for real-time guided biopsy (EBUS-TBNA). The procedure takes 20–45 minutes for diagnostic bronchoscopy; 60–120 minutes for complex EBUS or therapeutic procedures. Recovery in the procedure room takes 30–60 minutes.

Flexible bronchoscopy provides direct visualisation of the central airways with a diagnostic yield of 80–90% for endobronchial tumours visible to the bronchoscope. Bronchoalveolar lavage detects Pneumocystis jirovecii pneumonia with >90% sensitivity and identifies atypical infections in immunocompromised patients rapidly and non-invasively. EBUS-guided TBNA for mediastinal lymph node staging achieves 85–93% sensitivity for lung cancer mediastinal staging, with specificity approaching 100% — allowing accurate N2/N3 disease assessment without surgical mediastinoscopy and dramatically improving staging accuracy while avoiding surgical risk. Transbronchial cryobiopsy for interstitial lung disease achieves diagnostic yields of 75–80%, comparable to surgical lung biopsy, with a markedly lower morbidity profile. Therapeutically, bronchoscopic foreign body retrieval is successful in over 95% of cases; endobronchial tumour debulking with laser or cryotherapy restores airway patency in 70–85% of cases of central obstruction, improving dyspnoea and quality of life without open surgery.

Bronchoscopy is a safe procedure in experienced hands with a serious complication rate below 1%. The most clinically significant complications are oxygen desaturation and bronchospasm during the procedure, managed with supplemental oxygen, nebulised bronchodilators, and dose titration of sedation. Bleeding after transbronchial biopsy occurs in 1–4% of cases; massive haemorrhage requiring bronchial artery embolisation or surgery is very rare (<0.1%). Pneumothorax complicates approximately 1–5% of transbronchial lung biopsies (higher with cryobiopsy at 5–10%) and requires insertion of a chest drain in approximately half of these cases. Post-procedure fever lasting 24–48 hours (post-bronchoscopy fever) is common and usually self-limiting. Infection is rare when proper cleaning and disinfection protocols are followed. Sedation-related complications include respiratory depression, hypotension, and paradoxical disinhibition reactions (especially to benzodiazepines in elderly patients). The overall 30-day mortality directly attributable to diagnostic bronchoscopy is less than 0.1% in appropriately selected patients.

Patients are monitored in a recovery area for 1–2 hours following sedation until they are alert, cardiovascularly stable, and maintaining oxygen saturation on room air. The throat spray anaesthetic wears off within 1–2 hours, after which eating and drinking can resume. Throat soreness and mild haemoptysis (blood-stained sputum) after biopsy procedures are expected and typically resolve within 24 hours. Patients must not drive for 24 hours following sedation and should be accompanied home. Light activities can be resumed the same day; return to work is usually possible the next day. If a pneumothorax is excluded by a post-procedure X-ray (routinely obtained after transbronchial biopsy), patients may be discharged without a chest drain if there is no respiratory compromise. Results from BAL cultures are available within 24–72 hours; histopathological biopsy results take 5–7 working days; EBUS-TBNA cytology results may be available more rapidly. Follow-up is arranged to discuss results and plan further management.